[{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"ce35b65b-d866-4bdd-9060-4d005f982015","acronym":"","url":"https://clinicaltrials.gov/study/NCT04991025","created_at":"2022-10-21T17:11:24.974Z","updated_at":"2024-07-02T16:34:26.304Z","phase":"Phase 2","brief_title":"Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery","source_id_and_acronym":"NCT04991025","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/19/2022","start_date":" 10/19/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-06-13"},{"id":"2abe92f5-a7aa-49ec-831a-73b25aaf9f65","acronym":"TRAMP","url":"https://clinicaltrials.gov/study/NCT05960578","created_at":"2024-01-11T23:19:44.824Z","updated_at":"2024-07-02T16:34:36.939Z","phase":"Phase 2","brief_title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","source_id_and_acronym":"NCT05960578 - TRAMP","lead_sponsor":"University of Washington","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/06/2024","start_date":" 05/06/2024","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-10"},{"id":"8deded4a-9926-4f1a-a26a-90e378ae94dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577755","created_at":"2023-11-14T19:14:53.297Z","updated_at":"2024-07-02T16:35:08.364Z","phase":"Phase 2","brief_title":"Pomalidomide Treatment in Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT04577755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-22"},{"id":"dc0579d6-d285-4c4f-a4da-1f44bfe4d346","acronym":"","url":"https://clinicaltrials.gov/study/NCT06069024","created_at":"2023-10-05T16:11:22.043Z","updated_at":"2024-07-02T16:35:10.669Z","phase":"","brief_title":"Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide","source_id_and_acronym":"NCT06069024","lead_sponsor":"Qianfoshan Hospital","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2024-04-09"},{"id":"17106019-1f09-43d1-b5ca-ce2f02cc6783","acronym":"GLIOSTAR","url":"https://clinicaltrials.gov/study/NCT04573192","created_at":"2023-06-23T01:16:24.218Z","updated_at":"2024-07-02T16:35:10.988Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression","source_id_and_acronym":"NCT04573192 - GLIOSTAR","lead_sponsor":"Philogen S.p.A.","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Fibromun (onfekafusp alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-08"},{"id":"6f4512bb-8afc-4c34-a25f-189b0c54dc26","acronym":"GLIOASTRA","url":"https://clinicaltrials.gov/study/NCT05304663","created_at":"2022-03-31T17:52:52.829Z","updated_at":"2024-07-02T16:35:10.960Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression","source_id_and_acronym":"NCT05304663 - GLIOASTRA","lead_sponsor":"Philogen S.p.A.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Fibromun (onfekafusp alfa)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-08"},{"id":"be4f16e6-3542-42a3-8f39-b8e294f6cbed","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305145","created_at":"2021-01-18T20:52:42.915Z","updated_at":"2024-07-02T16:35:14.376Z","phase":"Phase 2","brief_title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","source_id_and_acronym":"NCT04305145","lead_sponsor":"Massachusetts General Hospital","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-03-15"},{"id":"2fd1f36d-538c-4925-82be-67b0b08c4340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04301076","created_at":"2021-01-18T20:51:47.723Z","updated_at":"2024-07-02T16:35:16.189Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATL)","source_id_and_acronym":"NCT04301076","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • CD2","pipe":"","alterations":" ","tags":["CD4 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-06"},{"id":"df710e35-6fee-433d-8b5e-2a0f0b481289","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846880","created_at":"2023-05-06T14:04:17.467Z","updated_at":"2024-07-02T16:35:19.162Z","phase":"Phase 1","brief_title":"VitD3 Supplementation in Patients With Multiple Myeloma","source_id_and_acronym":"NCT05846880","lead_sponsor":"Amany Keruakous, MD, MS.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-02-15"},{"id":"92d236cb-41f3-4477-91bc-450b492b95a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01054196","created_at":"2021-01-18T04:08:59.899Z","updated_at":"2025-02-25T14:31:39.955Z","phase":"Phase 1/2","brief_title":"Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study","source_id_and_acronym":"NCT01054196","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-01"},{"id":"bf2c24bb-0980-48a4-95ed-efc1d3846155","acronym":"","url":"https://clinicaltrials.gov/study/NCT02561273","created_at":"2021-01-18T12:24:07.010Z","updated_at":"2024-07-02T16:35:26.335Z","phase":"Phase 1/2","brief_title":"Combination Chemotherapy \u0026 Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT02561273","lead_sponsor":"University of Nebraska","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2023-12-13"},{"id":"450e3be9-d027-4ab5-af42-c83f193b46b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06134388","created_at":"2023-11-19T12:16:06.655Z","updated_at":"2024-07-02T16:35:28.801Z","phase":"Phase 3","brief_title":"Sulfasalazine in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06134388","lead_sponsor":"Tanta University","biomarkers":" BCL2 • BAX","pipe":"","alterations":" ","tags":["BCL2 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-11-18"},{"id":"7465a53d-edcc-499b-8a80-50f901ea6413","acronym":"HO147SMM","url":"https://clinicaltrials.gov/study/NCT03673826","created_at":"2021-01-18T18:01:13.776Z","updated_at":"2024-07-02T16:35:30.805Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM","source_id_and_acronym":"NCT03673826 - HO147SMM","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" PTPRC • NCAM1","pipe":"","alterations":" ","tags":["PTPRC • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/19/2018","start_date":" 11/19/2018","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-11-01"},{"id":"5766f363-23d7-4ddf-aa99-822a48d173b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02185820","created_at":"2021-02-04T20:52:56.667Z","updated_at":"2024-07-02T16:35:44.252Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)","source_id_and_acronym":"NCT02185820","lead_sponsor":"European Myeloma Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-06-30"},{"id":"5549ff6d-d0c0-4524-812c-e784acd2dec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305444","created_at":"2021-01-18T20:52:47.509Z","updated_at":"2024-07-02T16:35:49.171Z","phase":"Phase 2","brief_title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT04305444","lead_sponsor":"Zhejiang DTRM Biopharma","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • DTRM-555 • DTRMWXHS-12"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-02"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"4b7e0b24-03c6-4d32-b451-a9a4d7917763","acronym":"","url":"https://clinicaltrials.gov/study/NCT02120807","created_at":"2021-04-27T22:53:05.162Z","updated_at":"2024-07-02T16:35:56.991Z","phase":"Phase 1","brief_title":"Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas","source_id_and_acronym":"NCT02120807","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TNFA • CXCL1","pipe":"","alterations":" ","tags":["TNFA • CXCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 04/15/2014","start_date":" 04/15/2014","primary_txt":" Primary completion: 01/24/2023","primary_completion_date":" 01/24/2023","study_txt":" Completion: 01/24/2023","study_completion_date":" 01/24/2023","last_update_posted":"2023-01-26"},{"id":"52f8a9a1-95f2-46c1-9a42-1380744675d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02126553","created_at":"2021-01-18T09:51:35.162Z","updated_at":"2024-07-02T16:36:00.548Z","phase":"Phase 2","brief_title":"Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission","source_id_and_acronym":"NCT02126553","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/13/2014","start_date":" 11/13/2014","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2022-11-11"},{"id":"609b62e0-5459-4e6f-b8b3-1e6b3e397774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01495598","created_at":"2022-11-05T15:11:43.110Z","updated_at":"2024-07-02T16:36:01.485Z","phase":"Phase 1/2","brief_title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","source_id_and_acronym":"NCT01495598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 01/10/2012","start_date":" 01/10/2012","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-11-01"},{"id":"a6fd0405-fc77-45a8-8618-63d6afa0c28a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04797325","created_at":"2021-03-15T15:53:37.014Z","updated_at":"2024-07-02T16:36:05.376Z","phase":"Phase 2","brief_title":"Vedolizumab for Immune Mediated Colitis","source_id_and_acronym":"NCT04797325","lead_sponsor":"University of Copenhagen","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Entyvio (vedolizumab) • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-08-17"},{"id":"3a0c49c1-727b-492b-bc54-7034bb716618","acronym":"KMM1911","url":"https://clinicaltrials.gov/study/NCT05497102","created_at":"2022-08-15T11:10:45.029Z","updated_at":"2024-07-02T16:36:05.577Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","source_id_and_acronym":"NCT05497102 - KMM1911","lead_sponsor":"Samsung Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-08-12"},{"id":"d1c900c0-6be6-4f48-a584-6371c3f163ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01213732","created_at":"2021-01-18T04:52:19.623Z","updated_at":"2024-07-02T16:36:12.381Z","phase":"Phase 1","brief_title":"Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma","source_id_and_acronym":"NCT01213732","lead_sponsor":"Philogen S.p.A.","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Fibromun (onfekafusp alfa)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2022-04-15"},{"id":"16616776-3265-4cfa-b812-7fae8acc3d56","acronym":"","url":"https://clinicaltrials.gov/study/NCT04082910","created_at":"2021-01-18T19:59:30.543Z","updated_at":"2024-07-02T16:36:12.770Z","phase":"Phase 1/2","brief_title":"Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells","source_id_and_acronym":"NCT04082910","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/15/2019","start_date":" 09/15/2019","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-04-13"}]